Loading
The RANO criteria are the rules for judging on MRI whether a glioma is responding, stable or growing, and they allow for the false growth that radiotherapy can cause in the first months.
The Macdonald criteria measured only the contrast-enhancing part of a brain tumour. After chemoradiotherapy for glioblastoma, 20 to 30% of patients show a transient increase in enhancement (pseudoprogression), and antiangiogenic drugs reduce enhancement without a true antitumour effect. The Response Assessment in Neuro-Oncology working group proposed updated criteria for high-grade gliomas (Wen and colleagues, Journal of Clinical Oncology 2010) that also assess the non-enhancing tumour.
RANO 2.0 (Wen and colleagues, Journal of Clinical Oncology 2023) uses one set of criteria for high- and low-grade gliomas whatever the treatment. In newly diagnosed disease the scan after radiotherapy, not after surgery, is the baseline, and in the 12 weeks after radiotherapy progression needs a confirming MRI or tissue proof. Two-dimensional measurement remains primary with volume optional, and for IDH wild-type glioblastoma the non-enhancing disease is no longer assessed except with antiangiogenic drugs.
Showing the technology this term belongs to: MRI.
Shares iRANO (immunotherapy response in neuro-oncology), RECIST, MRI.
Shares RANO 2.0: Update to the Response Assessment in Neuro-Oncology Criteria for High- and Low-Grade Gliomas in Adults, Glioma & glioblastoma.
Shares iRANO (immunotherapy response in neuro-oncology), RECIST.
Shares MRI, Glioma & glioblastoma.
Shares RAPNO (paediatric brain tumour response criteria), iRANO (immunotherapy response in neuro-oncology), RECIST.
Shares MRI, Glioma & glioblastoma.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/